A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
Price : $35 *
At a glance
- Drugs Lifitegrast (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 03 Jan 2018 According to a Shire plc media release, Xiidra (lifitegrast ophthalmic solution 5%) has been approved in Canada for the treatment of dry eye disease based on results from five trials including this one.
- 15 Aug 2017 According to a Shire media release, based on the data from this and other four trials (see profiles 251148, 239561, 239552 and 239399), the Marketing Authorization Application (MAA) for lifitegrast, submitted on 07 August 2017, has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP) MAA was submitted to Denmark, Norway, Sweden, Finland, the UK, Germany, the Netherlands, France, Italy, Portugal, Spain and Greece.
- 14 Feb 2017 According to a Shire Pharma media release, company has filed a New Drug Submission (NDS) with Health Canada for the marketing authorization of lifitegrast for the treatment of dry eye disease in adults in Canada.